KINTOR PHARMA-B (09939) surged over 8% in morning trading. As of press time, the stock was up 8.52% to HK$2.42, with a turnover of HK$96.388 million.
On the news front, KINTOR PHARMA-B announced on September 9 that its independently developed novel high-efficiency tyrosinase inhibitor KT-939, designed to suppress melanin production, has recently completed enrollment of all 130 subjects for its long-term human safety trial. KT-939 can precisely target tyrosinase and effectively block the oxidation process of tyrosine, thereby effectively inhibiting melanin production while providing antioxidant and anti-inflammatory benefits, demonstrating outstanding advantages in cosmetic efficacy and safety.
As of the announcement date, KT-939 has completed multiple safety and toxicological evaluation trials as well as a 28-day continuous topical human efficacy trial. The trial results indicate that KT-939 demonstrates good performance in both efficacy and safety aspects.
Based on previous comparative studies of KT-939 against commonly used whitening ingredients such as Thiamidol and phenylethyl resorcinol (377) in terms of efficacy and safety, the company is actively advancing preparation work for KT-939's registration application, planning to formally submit the registration application to China's National Medical Products Administration in the third quarter of next year.
Thiamidol, a tyrosinase inhibitor with the same mechanism for targeting melanin production, was approved for registration by China's drug regulator in November 2024, becoming the first and currently only approved whitening agent cosmetic new ingredient since the implementation of the "Cosmetics Supervision and Administration Regulation" in 2021, and the second whitening agent cosmetic ingredient approved domestically in 12 years since 377.
KT-939 is expected to become China's first independently developed and approved whitening agent cosmetic new ingredient, achieving a "zero breakthrough" in complete independent intellectual property rights in this field for China, providing new options for the domestic and global spot-removal and whitening cosmetics market.